Avodart Real-World Response Rate: What Reddit, Clinical Trials, and Patient Reviews Actually Show

Dutasteride is the generic name for the oral 0.5 mg capsule sold under the brand name Avodart. It belongs to the 5-alpha reductase inhibitor class and blocks both type I and type II isoforms of the enzyme, which is why it is often described as a "dual" 5-ARI compared with finasteride, which blocks only type II. Dutasteride is FDA-approved for benign prostatic hyperplasia (BPH) and is not FDA-approved for hair loss in the United States, though it is used off-label for androgenetic alopecia (AGA) and holds that approval in South Korea and Japan.

The direct answer: In controlled trials, dutasteride produces a clinically meaningful reduction in urinary symptom scores for a majority of men with BPH, and measurable hair regrowth or shedding stabilization for a majority of men with AGA who continue treatment for six months or longer. The size of those majorities, and how "meaningful" is defined, varies by trial and by which endpoint is used, and several of the frequently cited exact percentages in circulation need to be checked against the primary trial publications before they are repeated as fact. What Reddit and drug-review sites show is a self-selected sample that tends to overrepresent side effects and dramatic outcomes in both directions, which is a different thing than a response rate.

What "response" means depends on who is measuring it

For BPH, clinical trials typically define response using the International Prostate Symptom Score (IPSS), a validated 0-to-35 questionnaire covering urinary frequency, urgency, stream strength, and nocturia. A "responder" in most published 5-ARI trials is someone whose IPSS drops by a pre-specified threshold, commonly around 3 to 4 points, from baseline.

For androgenetic alopecia, trials use hair counts per square centimeter of scalp, global photographic assessment by blinded investigators, or patient self-assessment questionnaires. These are different instruments than the ones used in BPH trials, and they are not directly comparable across indications.

Patients describing their own "response" on Reddit or review sites use neither instrument. Common patient-reported markers include fewer nighttime bathroom trips, a stronger urine stream, less post-void dribbling, and visible hairline or crown changes noticed in photos or mirrors. These are legitimate outcomes that matter to the person experiencing them, but they are not the same measurement as a validated trial endpoint, and a patient's subjective sense of "it's working" or "it's not working" can diverge from what a photographic or symptom-score assessment would show.

Dutasteride for BPH: what trials have shown

Three trials are central to the dutasteride BPH evidence base and are widely cited in urology literature: CombAT (a multi-year trial comparing dutasteride, tamsulosin, and the combination in men with enlarged prostates), REDUCE (a four-year trial primarily designed to study prostate cancer risk reduction, with BPH symptom scores as a secondary endpoint), and EPICS (a head-to-head comparison of dutasteride and finasteride). These trials generally report that:

• Dutasteride monotherapy improves IPSS scores compared with placebo, with the benefit becoming more pronounced over 12 to 24 months as prostate volume shrinks.
• Combining dutasteride with an alpha-blocker such as tamsulosin produces a larger symptom-score improvement than either drug alone, particularly in men with larger prostates and more severe baseline symptoms.
• Dutasteride and finasteride produce broadly similar urinary symptom improvement despite dutasteride's greater degree of DHT suppression, meaning higher DHT suppression does not appear to translate into a proportionally larger symptom benefit for BPH.

We are not restating the exact point-differences and percentage figures that circulate for these trials here, because the specific citation identifiers commonly attached to them could not be verified against the primary literature for this draft. Anyone using an exact number (for example, "IPSS improved by X points" or "Y% were responders at 24 months") should confirm it against the original CombAT, REDUCE, or EPICS publications or the FDA-approved Avodart prescribing information before using it in a clinical or patient-facing context.

Most men who respond to dutasteride for BPH notice some improvement in urine flow within the first one to two months, but the FDA label describes maximal prostate volume reduction as a slower process that continues over many months of continuous use. Stopping treatment before that window has elapsed is a common reason men conclude, incorrectly, that dutasteride "didn't work" for them.

Dutasteride for hair loss: what trials have shown

Dutasteride's AGA approval in South Korea and Japan was supported by phase III trials comparing dutasteride, finasteride, and placebo using hair counts and investigator global assessment. These trials, along with subsequent meta-analyses, have generally found dutasteride 0.5 mg produces greater hair count increases than finasteride 1 mg over roughly six months of treatment. This is a more consistent head-to-head finding than the BPH comparison above, likely because dutasteride's more complete DHT suppression matters more for a scalp-follicle endpoint than for prostate volume.

As with the BPH numbers, the exact hair-count figures and percentage-improvement statistics attached to these trials in secondhand summaries should be verified against the original publication before being treated as settled facts. A 2023 systematic review in JAMA Dermatology examined multiple 5-ARI trials for AGA and is a reasonable starting point for anyone wanting to check the underlying evidence, though the specific link for that review could not be confirmed as pointing to the correct article for this draft and should be re-located by the reviewing clinician before citation.

Because hair follicles cycle slowly, visible regrowth takes longer to appear than urinary symptom relief. Most dermatology sources recommend evaluating hair-loss treatment response only after a minimum of six months, with some improvement in shedding sometimes noticeable earlier.

What Reddit and patient reviews add, and where they mislead

Reddit communities such as r/HairLoss and r/BPH, and structured review platforms like Drugs.com, contain large volumes of patient-reported experience with dutasteride. Recurring themes include:

Reported as positive: reduced nighttime urination, stronger stream, and (for hair loss) continued regrowth in some users who say finasteride had stopped working for them before they switched. This last pattern is plausible given dutasteride's more complete DHT suppression, but no controlled trial has specifically tested "finasteride non-responders switched to dutasteride" as its primary question, so this remains an observational pattern rather than a proven strategy.

Reported as negative: sexual side effects (reduced libido, ejaculatory changes) are the most frequent complaint in online forums. Clinical trials also report these effects, generally in a single-digit percentage of dutasteride users versus a lower but nonzero percentage of placebo users, though online forums likely overrepresent this side effect relative to trial-measured rates because people who experience an unwanted effect are more motivated to post than people who have an uneventful course.

Aggregate star ratings on consumer review sites are a weak signal for response rate. A rating reflects overall satisfaction, which is shaped by side effects, cost, and expectations as much as by whether the drug met a validated clinical endpoint. Treat forum and review-site impressions as hypothesis-generating context, not as a substitute for trial data.

Evidence-review framework: separating what was reported from what was tested

This framework separates each type of dutasteride claim by its evidence source, states what can currently be concluded, flags what remains unresolved, and names the next decision a reader or clinician actually needs to make.

Side effects and monitoring points worth knowing

The FDA-approved Avodart prescribing information lists decreased libido, erectile dysfunction, and ejaculation disorders as the most common adverse effects reported in clinical trials, occurring more often than in placebo groups. Gynecomastia (breast tissue enlargement or tenderness) is also listed and is described as uncommon; it typically improves with dose adjustment or discontinuation, and any breast changes should be reported to a prescriber promptly rather than monitored alone.

Dutasteride suppresses PSA levels, which matters for prostate cancer screening interpretation. The American Urological Association's BPH guideline addresses PSA interpretation in men on 5-alpha reductase inhibitors; because dutasteride lowers PSA, a PSA value in a man taking dutasteride cannot be interpreted the same way as in a man who is not, and prescribers typically adjust their expectations of a "normal" PSA range accordingly rather than applying an untreated cutoff. Ask your prescriber how they are adjusting your specific PSA result rather than applying a general multiplier yourself.

In 2011, the FDA issued a drug safety communication updating labeling for 5-alpha reductase inhibitors, including dutasteride, regarding a possible association with a more aggressive form of prostate cancer identified in the REDUCE trial. As of that communication, the FDA characterized the absolute risk as small but directed that labeling reflect the signal. This is a regulatory-label-level fact as of 2011; men considering dutasteride, especially those with elevated baseline prostate cancer risk, should discuss this with a urologist rather than relying on forum discussion of the topic.

Dutasteride is contraindicated in women who are or may become pregnant and in children, because of the risk of harm to a male fetus from even skin contact with leaking or broken capsules. It is also contraindicated in severe hepatic impairment given its hepatic metabolism. Men taking dutasteride are advised by the FDA label not to donate blood for a period after stopping the drug, given its long elimination half-life; check the current label for the specific waiting period, since this is the kind of detail that can be updated.

Where the evidence is solid, where it is thin

Established: Dutasteride is FDA-approved for BPH and produces a measurable reduction in prostate volume and urinary symptom scores over sustained use, more so in combination with an alpha-blocker for men with larger prostates. It is not FDA-approved for hair loss in the United States. It suppresses PSA, meaning PSA interpretation must be adjusted for men on the drug. It carries an FDA-labeled signal regarding a possible link to more aggressive prostate cancer, based on the REDUCE trial.

Plausible but not settled at the level of exact numbers: The commonly repeated percentage figures for "response rate" in BPH and AGA trials are directionally consistent with published findings but the exact digits attached to them in secondary sources should be verified against the original trial publications before being used in clinical counseling or marketing copy. The idea that men who plateau on finasteride may see further benefit switching to dutasteride is mechanistically plausible and supported by patient reports, but has not been tested in a dedicated randomized trial.

Not established: There is no validated way to predict, before starting treatment, which individual patient will fall into the non-responder group. Genetic or biomarker testing for 5-alpha reductase sensitivity is not standard clinical practice. Long-term outcomes of Reddit-reported patterns such as persistent symptoms after stopping the drug have not been studied in controlled withdrawal trials, and drawing firm conclusions from those reports risks overgeneralizing from a self-selected, non-representative sample.

When to seek care rather than wait it out

New or worsening urinary retention, inability to urinate, blood in the urine, a new breast lump, or a PSA result flagged as concerning by your prescriber all warrant prompt medical evaluation rather than watchful waiting through a forum thread. Sexual side effects that are distressing or persistent should be discussed with your prescriber, since options include dose review, an alternative agent, or discontinuation rather than something to tolerate indefinitely. Anyone planning conception within the next several months should raise this with their prescriber before starting or continuing dutasteride, given documented effects on sperm parameters that are generally reversible but not universally so.

Frequently asked questions

References

• American Urological Association. Benign Prostatic Hyperplasia (BPH) Guideline. https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline

Specific numeric outcomes from these trials and related reviews are described qualitatively here, as reported figures vary between studies and have not been independently confirmed here.